- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:30 | Qiming Venture Partners: Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq | 169 | PR Newswire | SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq... ► Artikel lesen | |
| Mi | Attovia's Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders | 2 | MedCity News | ||
| Mi | Attovia adds to biotech IPO momentum with $289M offering | 1 | BioPharma Dive | ||
| Mi | Immune-focused biotech Attovia Therapeutics prices previously upsized IPO at $17, as expected | 2 | Renaissance Capital | ||
| ATTOVIA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO | 1 | FierceBiotech | ||
| Mi | Attovia Therapeutics prices upsized IPO at $17 per share, targets $289M raise | 1 | Seeking Alpha | ||
| Mi | Attovia Therapeutics prices upsized IPO at $17 per share | 1 | Investing.com | ||
| Mi | Attovia Therapeutics, Inc.: Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering | 50 | GlobeNewswire (Europe) | SAN CARLOS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia") (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for... ► Artikel lesen | |
| Di | Immune-focused biotech Attovia Therapeutics ups deal size by 45%, sets proposed price at $17 ahead of $289 million IPO | 1 | Renaissance Capital | ||
| Di | Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO | 6 | Reuters | ||
| Di | Goldman Sachs-backed Attovia eyes US$731.5 million valuation in upsized U.S. IPO | 3 | BNN Bloomberg | ||
| 30.07. | Braveheart Bio, Attovia seek $275M and $182M in U.S. IPOs | 1 | Seeking Alpha | ||
| 30.07. | Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs | 1 | FierceBiotech | ||
| 29.07. | Phase 1 immune system diseases biotech Attovia Therapeutics sets terms for $200 million IPO | 1 | Renaissance Capital | ||
| 29.07. | Attovia Therapeutics, Inc. - 8-A12B, Registration of securities | 3 | SEC Filings | ||
| 29.07. | Attovia Therapeutics, Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 16.07. | Two more biotechs, Attovia and Braveheart, join the IPO line | 1 | pharmaphorum | ||
| 15.07. | Braveheart, Attovia, Apnimed join gene therapy firm Scribe Therapeutics in July IPO rush | 3 | Seeking Alpha | ||
| 15.07. | Braveheart, Attovia join next wave of biotech IPOs | 1 | BioPharma Dive | ||
| 15.07. | Attovia files for IPO to take on Sanofi and Regeneron's Dupixent | 22 | FierceBiotech |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 134,21 | -0,01 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| AMYLYX PHARMACEUTICALS | 21,850 | 0,00 % | Amylyx Pharmaceuticals, Inc. - 10-Q, Quarterly Report | ||
| ENLIVEN THERAPEUTICS | 59,70 | 0,00 % | Enliven Therapeutics GAAP EPS of -$0.49 misses by $0.10 | ||
| VERA THERAPEUTICS | 30,380 | +0,10 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TREVI THERAPEUTICS | 18,650 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,170 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,300 | +0,07 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 47,290 | -0,11 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Second Quarter 2026 Financial Results | PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026 Phase 1 trial evaluating NBD1 stabilizer... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,710 | 0,00 % | Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights | - Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -
- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in... ► Artikel lesen | |
| ERASCA | 18,615 | -0,03 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 318,88 | -0,11 % | Praxis Precision Medicines Q2 2026 Earnings Preview | ||
| BICARA THERAPEUTICS | 25,890 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET | ||
| ARCUTIS BIOTHERAPEUTICS | 27,000 | -0,37 % | Arcutis raises 2026 net revenue guidance to $525M-$540M as ZORYVE demand expands and telehealth launches | ||
| CG ONCOLOGY | 72,41 | -0,01 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,080 | +0,04 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen |
Das Unternehmen ATTOVIA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATTOVIA THERAPEUTICS INC finden Sie auf Wallstreet Online.